The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

Orforglipron's launch and Medicare/Medicaid eligibility will expand Eli Lilly's addressable market and offset price erosion.

Dupixent growth offsets Eylea declines; pipeline/Libtayo impact post-2026; monitor ROIC & SBC. Click for a REGN update.

Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript March 12, 2026 Nektar Therapeutics beats earnings expectations. Reported EPS is $-1.77756, expectations were $-2.47411. Operator: ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

(Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 ...

The endometriosis market is expected to grow steadily over the forecast period (2026--2036), driven by rising disease awareness, improving diagnosis rates, and advancements in noninvasive diagnostic ...

Novo Nordisk NVO shares have plunged 22% in the past month, wiping out nearly $50 billion in market capitalization. Following ...

CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...

DelveInsight's CD-19 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...